Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phenylalanyl-tRNA synthetase (PheRS) is an essential housekeeping enzyme responsible for the precise attachment of the amino acid phenylalanine to its cognate tRNA (tRNA^Phe), a fundamental step in the translation of the genetic code into proteins. Structurally, the cytoplasmic enzyme is unique among the aminoacyl-tRNA synthetase family as a heterotetramer composed of two alpha (FARSA) and two beta (FARSB) subunits, and it is the only Class II enzyme that aminoacylates the 2'-OH group of the tRNA terminal ribose rather than the 3'-OH. In addition to its canonical role in translation, PheRS exhibits non-canonical functions such as DNA binding and the regulation of cell signaling pathways like Notch, which can promote cell growth and proliferation. Because of significant structural divergence between bacterial/parasitic PheRS and human counterparts, it has become a high-priority target for the development of novel anti-infectives, including antibacterials for resistant pathogens like Staphylococcus aureus and antimalarials for Plasmodium falciparum. Pathologically, mutations in the human mitochondrial variant (FARS2) lead to severe neurological disorders such as infantile-onset epileptic encephalopathy, while overexpression of the cytoplasmic subunits is frequently observed in various malignancies, correlating with poor prognosis and metastasis.
Competitive inhibition of the phenylalanine or ATP binding sites to prevent the formation of phenylalanyl-adenylate (Phe-AMP) and subsequent tRNA charging.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phenylalanyl-tRNA synthetase (PheRS).